Blood · 2014 · 85 citations · 43 references
MedicineHematologyImmunologyNeoplasiaHematologic MalignanciesHematopoietic NeoplasmsLymphoid NeoplasmsMyelodysplastic SyndromesMyeloproliferative NeoplasmsThrombosisJak2 MutationsJak2 V617f MutationMpl MutationsMyeloid NeoplasmsThrombopoietin Receptor Signaling
The most frequent contributing factor in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) is the acquisition of a V617F mutation in Janus kinase 2 (JAK2) in hematopoietic stem cells (HSCs). Recent evidence has demonstrated that to drive MPN transformation, JAK2V617F needs to directly associate with a functional homodimeric type I cytokine receptor, suggesting that, although acquiring JAK2V617F may promote disease, there are additional cellular components necessary for MPN development. Here we show that loss of the thrombopoietin (TPO) receptor (MPL) significantly ameliorates MPN development in JAK2V617F(+) transgenic mice, whereas loss of TPO only mildly affects the disease phenotype. Specifically, compared with JAK2V617F(+) mice, JAK2V617F(+)Mpl(-/-) mice exhibited reduced thrombocythemia, neutrophilia, splenomegaly, and neoplastic stem cell pool. The importance of MPL is highlighted as JAK2V617FMpl(+/-) mice displayed a significantly reduced MPN phenotype, indicating that Mpl level may have a substantial effect on MPN development and severity. Splenomegaly and the increased neoplastic stem cell pool were retained in JAK2V617F(+)Tpo(-/-) mice, although thrombocytosis was reduced compared with JAK2V617F(+) mice. These results demonstrate that Mpl expression, but not Tpo, is fundamental in the development of JAK2V617F(+) MPNs, highlighting an entirely novel target for therapeutic intervention.
43
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature · 2005 · 3.5K citations
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
Róbert Královics, Francesco Passamonti, Andreas Buser et al. · New England Journal of Medicine · 2005 · 3.5K citations · Full text
Life Sciences, Genetics, Hematology +15
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations
Life Sciences, Genetics, Hematology +14
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl, Heinz Gisslinger, Ashot S. Harutyunyan et al. · New England Journal of Medicine · 2013 · 2K citations · Full text
Medicine, Genetics, Hematology +14